Qiagen N.V.: stock overview

QGENNYSEHealthcare · Biological Products, (No Diagnostic Substances)

Price

$49.89

November 13, 2026Market cap $10.8B

DCF calculator

What Ploutos Investor adds for Qiagen

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Qiagen had revenue of $2.1B in the fiscal year to December 31, 2025 and net income of $425M, a net margin of 20.3%. Revenue grew by 2.3% a year on average over the last 5 years. At $49.89 the shares trade at a P/E of 25.5, against a median of 27.0 over the last 4 fiscal years. It has net debt of $556M. It pays a dividend yielding 0.50%.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$10.8B
217M shares
P/E
25.5
Today25.5
Median27.0
Revenue, fiscal year
$2.1B
+2.3% a year over 5 years
Net margin
20.3%
above 88% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+3.1% a year over 2 years

  • 202520-F
    Revenue$2.1B
  • 202420-F
    Revenue$2.0B
  • 202320-F
    Revenue$2.0B

Fiscal years in figures

QGEN's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $9.9B
$10.8B
Enterprise value 
$11.4B
P/E 
25.5
EV / EBIT 
24.4
EV / Revenue 
5.4
P/B 3-year median: 2.7
2.9
FCF yield 3-year median: 4.6%
4.2%
Earnings yield 3-year median: 3.3%
3.9%

Profitability

Gross margin 
62.2%
Operating margin 
22.3%
Net margin 3-year median: 17.4%
20.3%
ROIC 
6.8%
ROIC, 5-year average 
6.4%
ROE, fiscal year 
11.3%

Growth

Revenue, yearly change 
+5.7%
EPS, yearly change 
+424.3%
FCF, yearly change 
-10.5%
Revenue, average a year 
+2.3%
EPS, average a year 
+4.9%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$1.1B
Total debt 
$1.8B
Of which operating leases 
$158M
Net debt 
$556M
Net debt / EBITDA 
0.8x
Interest cover 
14.0x
Current ratio 
–

Balance sheet of December 31, 2025.

Returns to shareholders

Dividend yield 
0.50%
Buybacks 
2.59%
Total returned 
3.09%
Shares, yearly change 
-2.4%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

62.2%

Above 73% of the 141 companies in its industry, and 80% of all.

Operating margin

22.3%

Above 87% of the 285 companies in its industry, and 86% of all.

Net margin

20.3%

Above 88% of the 302 companies in its industry, and 82% of all.

ROE

11.3%

Above 69% of the 267 companies in its industry, and 65% of all.

ROA

6.8%

Above 75% of the 313 companies in its industry, and 79% of all.

Revenue growth

5.7%

Above 49% of the 292 companies in its industry, and 48% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
QIAGEN N.V.
CIK
1015820
Exchange
NYSE
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
217M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Qiagen's filings show?

These are Qiagen's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about QGEN

Didn't find what you were looking for?

Ask us
What is QGEN's market cap?

Qiagen N.V.'s market cap is $10.8B, at a price of $49.89 on November 13, 2026 and 217M shares.

What is QGEN's P/E?

QGEN's P/E is 25.5, on earnings per share of $1.94 in the fiscal year to December 31, 2025. The median over the last 4 fiscal years was 27.0.

How much revenue does QGEN have?

Qiagen had revenue of $2.1B in the fiscal year to December 31, 2025. Over the last 5 years it changed by +2.3% a year on average.

Does QGEN pay a dividend?

Yes. Qiagen paid $0.25 per share over the last 12 months, a yield of 0.50% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Qiagen N.V.'s SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.